Sarepta Therapeutics
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
公司地址 215 First Street, Suite 415, Cambridge, MA, USA, 02142
電話號碼 +1 617 274-4000
傳真號碼 +1 800 621-5203
公司網頁 https://www.sarepta.com
員工數量 835
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Louise Rodino-Klapac, PhD President, Research and Development and Technical Operations 美元 752.51K 24/04/2026
Mr. Ian Michael Estepan President and Chief Operating Officer 美元 740.53K 24/04/2026
Mr. Ryan H. Wong Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 480.12K 24/04/2026
Ms. Cristin L. Rothfuss Executive Vice President, Chief General Counsel and Corporate Secretary 美元 629.86K 24/04/2026
Mr. Douglas S. Ingram,Esq. Director and Chief Executive Officer 美元 1.17M 25/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Michael A. Chambers Independent Director 24/04/2026
Dr. Stephen L. Mayo, PhD Independent Director 24/04/2026
Dr. Kathryn Jean Boor, PhD Independent Director 24/04/2026
Mr. Richard J. Barry Independent Director 24/04/2026
Dr. Hans Wigzell, M.D.,PhD Independent Director 24/04/2026
Dr. Claude Nicaise,M.D. Independent Director 24/04/2026
Mr. Douglas S. Ingram,Esq. Director and Chief Executive Officer 25/02/2026
Ms. Deirdre P. Connelly Independent Director 24/04/2026
Dr. M. Kathleen Behrens Wilsey, PhD Chairwoman of the Board 24/04/2026
 
所屬ETF (更新日期: 02/05/2026 04:23)
代號 名稱 佔比% ▼ 持有日期
FTQIFirst Trust Nasdaq BuyWrite Income ETF<0.000001%27/08/2025
FTXHFirst Trust Nasdaq Pharmaceuticals ETF<0.000001%21/09/2025
GEWCambria Global EW ETF<0.000001%20/10/2025
GUSAGoldman Sachs MarketBeta US 1000 Eq ETF<0.000001%07/08/2025
HAPYHarbor Human Capital Factor Uncons ETF<0.000001%13/09/2025
HKNDHumankind US Stock ETF<0.000001%24/11/2025
IDNAiShares Genomics Immnlgy & Hlthcr ETF<0.000001%06/03/2026
IJHiShares Core S&P Mid-Cap ETF<0.000001%05/03/2026
IJJiShares S&P Mid-Cap 400 Value ETF<0.000001%05/03/2026
IJKiShares S&P Mid-Cap 400 Growth ETF<0.000001%06/03/2026
IQSMNYLI Candriam U.S. Mid Cap Equity ETF<0.000001%22/09/2025
ISCGiShares Morningstar Small-Cap Growth ETF<0.000001%06/03/2026
IUSGiShares Core S&P US Growth ETF<0.000001%06/03/2026
IUSViShares Core S&P US Value ETF<0.000001%06/03/2026
IVOGVanguard S&P Mid-Cap 400 Growth ETF<0.000001%31/08/2025
IVOOVanguard S&P Mid-Cap 400 ETF<0.000001%30/09/2025
IYYiShares Dow Jones US ETF<0.000001%06/03/2026
JCTRJPMorgan Carbon Transition US Eq ETF<0.000001%07/10/2025
JHMLJHancock Multifactor Large Cap ETF<0.000001%18/09/2025
JHMMJHancock Multifactor Mid Cap ETF<0.000001%18/09/2025
  1    2    3    4    5    6   7    8    9  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.